• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

    54.19 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 6,841
    Open 54.19
    Bid (Size) 53.61 (1,700)
    Ask (Size) 54.00 (7,600)
    Prev. Close 54.19
    Today's Range 54.19 - 54.19
    52wk Range 36.08 - 78.48
    Shares Outstanding 78,935,098
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking ↗
    This little-discussed pipeline program could prove to be a big success. 
    Via The Motley Fool
    News headline image
    CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? ↗
    One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026. 
    Via The Motley Fool

    Performance

    YTD
    +0.8%
    +0.8%
    1 Month
    +1.1%
    +1.1%
    3 Month
    -10.8%
    -10.8%
    6 Month
    +3.9%
    +3.9%
    1 Year
    +46.7%
    +46.7%

    More News

    Read More
    News headline image
    Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? ↗
    Via The Motley Fool
    News headline image
    The Best Stocks to Invest $3,000 In Right Now ↗
    Via The Motley Fool
    News headline image
    CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms ↗
    Via MarketBeat
    Topics Intellectual Property
    News headline image
    1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? ↗
    Via The Motley Fool
    News headline image
    Is This Millionaire-Maker Biotech Stock a Buy Right Now? ↗
    Via The Motley Fool
    Topics Initial Public Offering
    News headline image
    Want to Build Real Wealth in Healthcare? These Stocks Are Worth Considering ↗
    Via The Motley Fool
    News headline image
    What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer. ↗
    Via The Motley Fool
    News headline image
    Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead? ↗
    Via The Motley Fool
    News headline image
    3 Growth Stocks That Could Generate 10X Returns ↗
    Via The Motley Fool
    Topics Cannabis Law Enforcement
    News headline image
    3 Biotech Stocks That Could Benefit from the Patent Cliff ↗
    Via MarketBeat
    Topics Intellectual Property
    News headline image
    CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? ↗
    Via The Motley Fool
    News headline image
    2 Billion Reasons to Love CRISPR Therapeutics Right Now ↗
    Via The Motley Fool
    News headline image
    This Biotech Has a Pipeline That Could Redefine Its Entire Therapeutic Area ↗
    Via The Motley Fool
    News headline image
    Is This Biotech Stock Your Best Shot at Building a Millionaire-Making Position? ↗
    Via The Motley Fool
    Topics ETFs
    News headline image
    CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now? ↗
    Via The Motley Fool
    News headline image
    Vertex Pharmaceuticals (VRTX): The Evolution of a Biotech Powerhouse in 2026
    Via Finterra
    Topics Intellectual Property
    News headline image
    Is CRISPR Therapeutics Stock a Buy Now? ↗
    Via The Motley Fool
    News headline image
    3 Monster Stocks to Hold for the Next 10 Years ↗
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    This Is Why CRISPR Therapeutics Stock Is Tumbling on Tuesday ↗
    Via The Motley Fool
    News headline image
    Why Is CRSP Stock Falling Pre-Market Today? ↗
    Via Stocktwits
    News headline image
    RIVN Stock Gains 4% Pre-Market After TD Cowen Upgrade: Analyst Sees Strong Demand For Upcoming R2 Models ↗
    Via Stocktwits
    Topics Electric Vehicles
    News headline image
    Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of ↗
    Via The Motley Fool
    News headline image
    Is CRISPR Therapeutics Stock Too Risky to Buy Right Now? ↗
    Via The Motley Fool

    Frequently Asked Questions

    Is CRISPR Therapeutics AG - Common Shares publicly traded?
    Yes, CRISPR Therapeutics AG - Common Shares is publicly traded.
    What exchange does CRISPR Therapeutics AG - Common Shares trade on?
    CRISPR Therapeutics AG - Common Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for CRISPR Therapeutics AG - Common Shares?
    The ticker symbol for CRISPR Therapeutics AG - Common Shares is CRSP on the Nasdaq Stock Market
    What is the current price of CRISPR Therapeutics AG - Common Shares?
    The current price of CRISPR Therapeutics AG - Common Shares is 54.19
    When was CRISPR Therapeutics AG - Common Shares last traded?
    The last trade of CRISPR Therapeutics AG - Common Shares was at 06/01/26 04:00 PM ET
    What is the market capitalization of CRISPR Therapeutics AG - Common Shares?
    The market capitalization of CRISPR Therapeutics AG - Common Shares is 4.28B
    How many shares of CRISPR Therapeutics AG - Common Shares are outstanding?
    CRISPR Therapeutics AG - Common Shares has 4B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.